Skip to main content

UC Davis Health System

James D. Brandt, M.D. View profile as PDF

James D. Brandt

Clinical Interests

Dr. Brandt has research interests in both the clinical and basic realms. In clinical research, he is a principal investigator in the landmark Ocular Hypertension Treatment Study and was largely responsible for one of the Study's most important findings to date, that thin corneal thickness is a risk factor for the development of glaucoma. Dr. Brandt is actively involved in large clinical trials investigating new medical and surgical treatments of glaucoma and new technologies for diagnosing the disease. In the basic research arena, Dr. Brandt is currently collaborating with Dr. Tingrui Pan of the Department of Biomedical Engineering to develop new MEMS and Nanotechnology-based devices for the diagnosis of glaucoma.


Director of the Glaucoma Service




Ophthalmology and Vision Science



Center/Program Affiliation:


Lawrence J. Ellison Ambulatory Care Center
* Lawrence J. Ellison Ambulatory Care Center
4860 Y St.,, Suite 0100
Sacramento, CA 95817
Driving Directions
Phone: 916-734-6602

Additional Phone:

Physician Referrals: 800-4-UCDAVIS (800-482-3284)


M.D., Harvard Medical School, Boston, Massachusetts, 1982
B.S., Yale University, New Haven, Connecticut, 1978


University of Minnesota Hospitals, Minneapolis, Minnesota, 1982-1983


University of Southern California, Los Angeles, California, 1983-1985


Harvard Medical School - Eye Research Institute, Boston, Massachusetts, 1983-1985
Wills Eye Hospital, Philadelphia, Pennsylvania, 1988-1989

Board Certifications:

American Board of Ophthalmology, 1989

Professional Memberships:

American Academy of Ophthalmology
American Glaucoma Society
American Medical Association
Association for Research in Vision and Ophthalmology
California Association of Eye Physicians and Surgeon
California Medical Association
Glaucoma Research Society
Massachusetts Medical Society
World Glaucoma Association

Select Recent Publications:

Brandt JD, Beiser JA, Gordon MO, Lin SC, Alexander MY, Kass MA and the OHTS Study Group Changes in Central Corneal Thickness Over Time: The Ocular Hypertension Treatment Study Ophthalmology 115(9):[in press]

Brandt JD, Cantor LB, Katz LJ, Batoosingh AL, Chou C & Bossowska I for the Ganfort Investigators Group II Bimatoprost/Timolol fixed combination: A 3-month double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension Journal of Glaucoma 17(3):211-216

Shah S, Al-Rajhi A, Brandt JD, Mannis MJ, Roos B, Sheffield VC, Stone EM & Fingert JH Mutation in SLC4A11 Gene Associated with Autosomal Recessive Congenital Hereditary Endothelial Dystrophy in a Large Saudi Family Ophthalmic Genetics 29(1):41-45

Gedde, SJ, Schiffman JC, Feuer WJ, Herndon LW, Brandt JD, Budenz DL and the Tube versus Trabeculectomy Study Group Treatment Outcomes in the Tube versus Trabeculectomy Study after One Year of Follow-up American Journal of Ophthalmology 143:9-22

Zangwill LM, Weinreb RN, Beiser J, Berry CC, Cioffi GA, Coleman AL, Trick G, Liebmann JM, Brandt JD, Piltz-Seymour JR, Dirkes KA, Vega S, Kass MA, Gordon MO and the Ocular Hypertension Treatment CSLO Ancillary Study Group Baseline topographic optic disc measurements predict the onset of primary open angle glaucoma: The Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study Archives of Ophthalmology 123(9):1188-1197

Brandt, JD, Beiser JA, Gordon MO & Kass MA for the Ocular Hypertension Treatment Study Group Central Corneal Thickness and IOP Response to Topical Ocular Hypotensive Medication in the Ocular Hypertension Treatment Study (OHTS)

Budenz, DL, Gedde SJ, Brandt JD, Kira DT, Feuer W & Larson E Baerveldt Glaucoma Implant in the Management of Refractory Childhood Glaucoma Ophthalmology 111(12):2204-2210

Gordon MO, Beiser JA, Brandt JD, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK, Wilson MR, Kass MA and the Ocular Hypertension Treatment Study Group The Ocular Hypertension Treatment Study: Baseline Factors that Predict the Development of Primary Open Angle Glaucoma Archives of Ophthalmology 120(6):714-720

Cioffi, G. A., J. D. Brandt, and D. Gagliuso, Cases in controversy: Early detection of glaucoma. Journal of Glaucoma 1998;7(3):182-186

Putney, L. K., J. D. Brandt, and M. E. O'Donnell Effects of dexamethasone on Na-K-Cl contransport activity and protein expression in trabecular meshwork cells. Investigative Ophthalmology & Visual Science 1997;38(6):1229-1240

Siegner, S. W., P. A. Netland, R. C. Urban, A. S. Williams, D. W. Richards, M. A. Latina and J. D. Brandt. Clinical Experience with the Baerveldt glaucoma drainage implant. Ophthalmology 1995;102(9):1298-1307

Johnson, C. A. and J. D. Brandt, A. M. Khong & A. J. Adams. Short wavelength automated perimetry (SWAP) in low, medium and high risk ocular hypertensives. Archives of Ophthalmology 1995;113(1):70-76

O’Donnell, M. E., J. D. Brandt, and F-R E. Curry. Na-K-Cl contransport regulates intracellular volume and monolayer permeability of trabecular meshwork cells. American Journal of Physiology (Cell Physiolo.) 1995;37: C1067-1074

To see if James D. Brandt is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).